November 27, 2012 at 13:56 PM EST
UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility
Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS ) with an Equal-weight rating and a $21 price target. Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here